Provenge Significantly Improves Survival Advanced Prostate Cancer

Dendreon Corporation has announced that Provenge, the Company's investigational immunotherapy for the treatment of prostate cancer, significantly improved survival in men with asymptomatic, metastatic androgen-independent (hormone-refractory) prostate cancer when compared to patients who were receiving placebo.This is a three-year intent-to-treat analysis of the Company's first randomized Phase 3 clinical study, in which patients receiving Provenge had a 4.5 month improvement in their median survival and a greater than 3-fold increase in survival at 36 months when compared to patients receiving placebo. Provenge is designed to stimulate a patient's immune system against prostate cancer cells. It is developed through Dendreon's proprietary Antigen Delivery Cassette technology, which utilizes a recombinant form of an antigen found in 95 percent of prostate cancers, prostatic acid phosphatase (PAP). Provenge is being further evaluated in an ongoing, another pivotal Phase 3 trial (D9902B) under a Special Protocol Assessment agreement with the U.S. Food and Drug Administration.To learn more about the trial, go to www.dendreon.com.